Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5616047 | 0.85 | TLR7 (0.33) | TLR7 | |
| SCHEMBL5616279 | 0.85 | — | — | |
| SCHEMBL5616060 | 0.85 | — | — | |
| SCHEMBL5616277 | 0.85 | — | — | |
| SCHEMBL4316570 | 0.84 | PDE4A (0.32) | TLR8TLR7 | |
| SCHEMBL4313859 | 0.84 | TLR7 (0.33) | TLR8TLR7 | |
| SCHEMBL5335318 | 0.83 | PDE4A (0.32) | TLR8TLR7 | |
| SCHEMBL4317790 | 0.82 | PDE4A (0.34) | TLR8TLR7 | |
| SCHEMBL5617166 | 0.81 | TNF (0.39) | TLR7 | |
| SCHEMBL4792410 | 0.80 | TDP1 (0.40) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR8 139/4885TLR7 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.